Cargando…

Renal manifestations of hepatitis E among immunocompetent and solid organ transplant recipients

Hepatitis E virus (HEV) infections are generally self-limited. Rare cases of hepatitis E induced fulminant liver failure requiring liver transplantation are reported in the literature. Even though HEV infection is generally encountered among developing countries, a recent uptrend is reported in deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovvuru, Karthik, Carbajal, Nicholas, Pakanati, Abhinandan Reddy, Thongprayoon, Charat, Hansrivijit, Panupong, Boonpheng, Boonphiphop, Pattharanitima, Pattharawin, Nissaisorakarn, Voravech, Cheungpasitporn, Wisit, Kanduri, Swetha R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055200/
https://www.ncbi.nlm.nih.gov/pubmed/35582296
http://dx.doi.org/10.4254/wjh.v14.i3.516
Descripción
Sumario:Hepatitis E virus (HEV) infections are generally self-limited. Rare cases of hepatitis E induced fulminant liver failure requiring liver transplantation are reported in the literature. Even though HEV infection is generally encountered among developing countries, a recent uptrend is reported in developed countries. Consumption of unprocessed meat and zoonosis are considered to be the likely transmission modalities in developed countries. Renal involvement of HEV generally holds a benign and self-limited course. Although rare cases of cryoglobulinemia are reported in immunocompetent patients, glomerular manifestations of HEV infection are frequently encountered in immunocompromised and solid organ transplant recipients. The spectrum of renal manifestations of HEV infection include pre-renal failure, glomerular disorders, tubular and interstitial injury. Kidney biopsy is the gold standard diagnostic test that confirms the pattern of injury. Management predominantly includes conservative approach. Reduction of immunosuppressive medications and ribavirin (for 3-6 mo) is considered among patients with solid organ transplants. Here we review the clinical course, pathogenesis, renal manifestations, and management of HEV among immunocompetent and solid organ transplant recipients.